Ana M Gonzalez-Angulo - JoVE Visualize

Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Policies

Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Policies

Filters

Ana M Gonzalez-Angulo

Showing results (131-140 of 144) with videos related to

Pageof 15

Sort By:

Clinical Breast Cancer|July 29, 2014

Analysis of MET genetic aberrations in patients with breast cancer at MD Anderson Phase I unitDebora de Melo Gagliato, Denis L Fontes Jardim, Gerald Falchook, et al.

Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 7, 2014

Recommendations on disease management for patients with advanced human epidermal growth factor receptor 2-positive breast cancer and brain metastases: American Society of Clinical Oncology clinical practice guidelineNaren Ramakrishna, Sarah Temin, Sarat Chandarlapaty, et al.

Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 22, 2015

Use of Biomarkers to Guide Decisions on Systemic Therapy for Women With Metastatic Breast Cancer: American Society of Clinical Oncology Clinical Practice GuidelineCatherine Van Poznak, Mark R Somerfield, Robert C Bast, et al.

Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 7, 2014

Systemic therapy for patients with advanced human epidermal growth factor receptor 2-positive breast cancer: American Society of Clinical Oncology clinical practice guidelineSharon H Giordano, Sarah Temin, Jeffrey J Kirshner, et al.

International Journal of Radiation Oncology, Biology, Physics|April 10, 2007

Postmastectomy radiation improves the outcome of patients with locally advanced breast cancer who achieve a pathologic complete response to neoadjuvant chemotherapySean E McGuire, Ana M Gonzalez-Angulo, Eugene H Huang, et al.

Breast Cancer Research and Treatment|April 28, 2012

Mutation profiling identifies numerous rare drug targets and distinct mutation patterns in different clinical subtypes of breast cancersLibero Santarpia, Yuan Qi, Katherine Stemke-Hale, et al.

Oncotarget|January 22, 2015

Functional consequence of the MET-T1010I polymorphism in breast cancerShuying Liu, Funda Meric-Bernstam, Napa Parinyanitikul, et al.

Journal of the National Cancer Institute|February 18, 2015

SU2C phase Ib study of paclitaxel and MK-2206 in advanced solid tumors and metastatic breast cancerAna M Gonzalez-Angulo, Ian Krop, Argun Akcakanat, et al.

Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 4, 2009

High risk of recurrence for patients with breast cancer who have human epidermal growth factor receptor 2-positive, node-negative tumors 1 cm or smallerAna M Gonzalez-Angulo, Jennifer K Litton, Kristine R Broglio, et al.

Proceedings of the National Academy of Sciences of the United States of America|May 19, 2010

PIK3CA mutations associated with gene signature of low mTORC1 signaling and better outcomes in estrogen receptor-positive breast cancerSherene Loi, Benjamin Haibe-Kains, Samira Majjaj, et al.

Pageof 15

Search research articles

Showing results (131-140 of 144) with videos related to

Sort By:

Pageof 15

Clinical Breast Cancer|July 29, 2014

Analysis of MET genetic aberrations in patients with breast cancer at MD Anderson Phase I unitDebora de Melo Gagliato, Denis L Fontes Jardim, Gerald Falchook, et al.

Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 7, 2014

Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 22, 2015

Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 7, 2014

International Journal of Radiation Oncology, Biology, Physics|April 10, 2007

Breast Cancer Research and Treatment|April 28, 2012

Mutation profiling identifies numerous rare drug targets and distinct mutation patterns in different clinical subtypes of breast cancersLibero Santarpia, Yuan Qi, Katherine Stemke-Hale, et al.

Oncotarget|January 22, 2015

Functional consequence of the MET-T1010I polymorphism in breast cancerShuying Liu, Funda Meric-Bernstam, Napa Parinyanitikul, et al.

Journal of the National Cancer Institute|February 18, 2015

SU2C phase Ib study of paclitaxel and MK-2206 in advanced solid tumors and metastatic breast cancerAna M Gonzalez-Angulo, Ian Krop, Argun Akcakanat, et al.

Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 4, 2009

Proceedings of the National Academy of Sciences of the United States of America|May 19, 2010

PIK3CA mutations associated with gene signature of low mTORC1 signaling and better outcomes in estrogen receptor-positive breast cancerSherene Loi, Benjamin Haibe-Kains, Samira Majjaj, et al.

Pageof 15